Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects

Thiazolidinediones (TZDs), among which Rosiglitazone, are known agonists of the peroxisome-proliferator-activated receptor γ (PPARγ) commonly used for treatment of hyperglycemia. A recently published article describing a case report on a patient affected by Fibrodysplasia Ossificans Progressiva (FOP...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bocciardi, Renata, Ravazzolo, Roberto
Formato: Artigo
Lenguaje:Inglês
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2896849/
https://ncbi.nlm.nih.gov/pubmed/20613955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/541927
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares